Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans

Therapeutic Drug Monitoring

Volumn 21, Issue 5, 1999, Pages 507-513

  Nakajima, Miki ^a,c   Suzuki, Takashi ^b   Sasaki, Tadanori ^a   Yokoi, Tsuyoshi ^c   Hosoyamada, Akiyoshi ^b   Yamamoto, Toshinori ^a   Kuroiwa, Yukio ^a  

^a Kitasato University   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

CYP3A4; Drug interaction; Induction; UDP glucuronosyltransferase

Indexed keywords

GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE; MIDAZOLAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; DRUG INTERACTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; INPATIENTS; MALE; MIDAZOLAM; MIDDLE AGED; TIME FACTORS;

EID: 0032836340     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199910000-00003     Document Type: Article

References (31)

1. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol Exp Ther 1994;270:414-23.
2. Krishna DR, Klotz U. Extrahepatic metabolism of drug in humans. Clin Pharmacokinet 1994;26:144-60.
3. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60: 14-24.
4. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59: 491-502.
5. Pieri L, Schaffer R, Scherschlicht R, et al. Pharmacology of midazolam. Arzneim-Forsch 1981;31:2180-201.
6. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolem administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992;20:1123-6.
7. 14C-midazolam following oral dosing. Arzneim-Forsch 1981;31: 2220-3.
8. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P-450IIIA4. Mol Pharmacol 1989;36:89-96.
9. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
10. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed l'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res 1994;11: 921-4.
11. Wandel C, Böcker R, Böhrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658-61.
12. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450-3A probe: II. Characterization of interand intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
13. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P4503A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
14. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
15. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmcodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-6.
16. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
17. Backman JT, Olkkola KT, Ojala M, et al. Concentration and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37:253-7.
18. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Phamacol Ther 1996;59:7-13.
19. Watkins PB, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985;82:6310-4.
20. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450. J Clin Invest 1989;83:688-97.
21. Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase in primary cultures of human hepatocytes. Mol Pharmacol 1992;41: 1047-55.
22. Puglisi CV, Pao J, Ferrara FJ, deSilva JAF. Determination of midazolam (Versed®) and its metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1985;344:199-209.
23. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16: 43S-9S.
24. Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effects of age, gender, and obesity on midazolam kinetics. Anesthesioloqy 1984; 61:27-35.
25. p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem 1986;261:8270-5.
26. Ferrari L, Herber R, Batt A-M, Siest G. Differential effects of human recombinant interleukin-1β and dexamethasone on hepatic drug-metabolizing enzymes in male and female rats. Biochem Pharmacol 1993;45:2269-77.
27. Leakey JEA, Althaus ZR, Bailey JR, Slikker WJr. Dexamethasone increase UDP-glucuronyltransferase activity towards bilirubin, oestradial and testosterone in foetal liver from rhesus monkey during late gestation. Biochem J 1985;225:183-8.
28. Doostdar H, Grant MH, Melvin WT, Wolf CR. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HepG2 hepatoma cells. Biochem Pharmacol 1993;46:629-35.
29. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30:653-61.
30. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipinerifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-3.
31. Kolars JC, Schmiedlin-Ren P, Schetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.